The Wolverine Stack pairs BPC-157 and TB-500 in a single vial — the two most commonly co-administered peptides in tissue-repair research, and the base every other blend on this site builds on. Here's what each compound contributes, and what's confirmed versus assumed about combining them.
What's in a Wolverine Stack
A standard vial is BPC-157 and TB-500 co-lyophilized in a 1:1 ratio — commonly 10mg of each, 20mg total. Reconstitution and dosing math work the same as for either compound alone; the calculator on this site handles mixed-vial concentration the same way.
Two Different Mechanisms in One Vial
BPC-157 is a synthetic pentadecapeptide first identified from a protective protein in gastric juice. In tendon fibroblasts, it activates the FAK–paxillin pathway, which researchers have linked to increased fibroblast outgrowth, better cell survival under stress, and increased migration from tendon explants.
TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein your cells use during repair. Its defining mechanism is different from BPC-157's: it binds actin, and the original 1997 study showed it acts as a chemoattractant for endothelial cells — stimulating migration four- to six-fold in vitro. A later review describes thymosin beta-4 more broadly as promoting the mobilization, migration, and differentiation of stem and progenitor cells that go on to form new blood vessels.
Why the Two Are Paired
The two mechanisms are complementary rather than redundant: BPC-157's studied effects center on local tissue survival and fibroblast activity at the injury site, while TB-500's studied effect is recruiting and moving the cells that populate the surrounding area. Vendors and researchers who stack the two are, in effect, targeting the repair site and the cell-migration pipeline feeding it in the same reconstitution.
What's not established: neither compound's studies were designed to test the combination. Each peptide's evidence base comes from studies where it was administered alone. Combining two well-studied peptides is not the same as having a study of the combination — that's a real gap, not a technicality.
For the full mechanism and regulatory-status writeup on BPC-157 specifically, see the complete BPC-157 research guide.
Sourcing the Wolverine Stack
We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis for the finished blend, not just the individual peptides.
View the Wolverine Stack product page →Frequently Asked Questions
Has the BPC-157 + TB-500 combination itself been studied, or just each peptide separately?
Just each peptide separately, as far as the published literature shows. BPC-157's evidence and TB-500's evidence both come from studies administering each compound alone. No co-administration trial for the specific combination was found in the literature reviewed for this guide.
References
1. Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon fibroblasts." PubMed
2. Malinda KM, Goldstein AL, Kleinman HK. "Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells." FASEB J, 1997. PubMed
3. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." PubMed
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.